The Money Runner
Gilead’s (GILD) $1000 Pill
By David Nelson, CFA Gilead (GILD) was ground zero for the Biotech sell-off. The sector is down about 25% from its highs made earlier in the year and now (GILD) may be where the sector makes its stand. Unlike Amazon (AMZN), Netflix (NFLX), Tesla (TSLA) and others that have been hit hard by the recent […]
BNN In-Depth Interview – S&P – China – Trouble in the Biotech Sector
http://youtu.be/NNA4-dtosbI David talks with BNN host Mark Bunting about a range of topics on investors minds. Biotechs, the Fed, Index Investing are all covered during this in-depth interview.
